These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

51 related articles for article (PubMed ID: 30738121)

  • 1. Images of the month: Gliptin-induced bullous pemphigoid.
    Orekoya O; Coulson IH
    Clin Med (Lond); 2021 Jan; 21(1):e112-e113. PubMed ID: 33479092
    [No Abstract]   [Full Text] [Related]  

  • 2. Bullous pemphigoid triggered by dulaglutide: a case report and a review of the literature.
    Sonego B; Zelin E; Zalaudek I; di Meo N
    Dermatol Reports; 2023 Sep; 15(3):9676. PubMed ID: 37822982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitor showing unfavorable outcomes despite immediate discontinuation of medication.
    Shinohara Y; Iijima T; Sakurai S; Jojima T; Ohira E; Hayashi S; Usui I; Igawa K; Aso Y
    Clin Case Rep; 2020 Oct; 8(10):2007-2012. PubMed ID: 33088540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Esophageal involvement in DPP4 inhibitor-associated bullous pemphigoid.
    Brufau-Cochs M; Alamon-Reig F; Luque-Luna M; Bosch-Amate X; Moreta MJ; Bassegoda O; Mascaró JM
    J Dtsch Dermatol Ges; 2024 Mar; 22(3):430-432. PubMed ID: 38286622
    [No Abstract]   [Full Text] [Related]  

  • 5. Glucagon Peptide Family and Adipose Tissue: Not that Intimate, just Acquaintances.
    Perez-Tilve D
    Endocrinology; 2020 Feb; 161(2):. PubMed ID: 31950149
    [No Abstract]   [Full Text] [Related]  

  • 6. First case of acquired hemophilia A in the context of vildagliptin-induced bullous pemphigoid.
    Patoulias D; Michailidis T; Dimosiari A
    Hippokratia; 2022; 26(1):48. PubMed ID: 37124275
    [No Abstract]   [Full Text] [Related]  

  • 7. Pemphigoid Nodularis Induced by Long-Term Use of Dipeptidyl Peptidase-4 Inhibitors.
    Norikawa N; Irie K; Ishikawa M; Hiraiwa T; Izumi K; Yamamoto T
    Indian J Dermatol; 2023; 68(1):104-105. PubMed ID: 37151239
    [No Abstract]   [Full Text] [Related]  

  • 8. Glucagon-Like Peptide 1 Receptor Agonist Use Before Surgery-Reply.
    Potnuru PP; Hernandez N; Sen S
    JAMA Surg; 2024 Sep; 159(9):1093-1094. PubMed ID: 39018041
    [No Abstract]   [Full Text] [Related]  

  • 9. What is a case-control study? Comment on 'Oral midodrine does not expedite liberation from protracted vasopressor infusions: A case-control study'.
    Myles PS
    Anaesth Intensive Care; 2024 Jan; 52(1):73. PubMed ID: 38000004
    [No Abstract]   [Full Text] [Related]  

  • 10. Response to "What is a case-control study? Comment on 'Oral midodrine does not expedite liberation from protracted vasopressor infusions: A case-control study'".
    Wood AJ; Rauniyar R; Jacques A; Palmer RN; Wibrow B; Anstey MH
    Anaesth Intensive Care; 2024 Jan; 52(1):74. PubMed ID: 37999999
    [No Abstract]   [Full Text] [Related]  

  • 11. Shifting Trends in the Indication of Glucagon-like Peptide-1 Receptor Agonist Prescriptions: A Nationwide Analysis.
    Yeo YH; Rezaie A; Hsieh TY; Hu X; Gaddam S; Ma KS; ; Mohamed G; Lee GY; Huang PC; Watson R
    Ann Intern Med; 2024 Sep; 177(9):1289-1291. PubMed ID: 39038291
    [No Abstract]   [Full Text] [Related]  

  • 12. Reply to: "Comment on 'Oral diabetes medications other than dipeptidyl peptidase-4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case-control study' and a case report of glucagon-like peptide-1 receptor agonist-induced bullous pemphigoid".
    Varpuluoma O; Tasanen K; Huilaja L
    J Am Acad Dermatol; 2019 Jun; 80(6):e191-e192. PubMed ID: 30738121
    [No Abstract]   [Full Text] [Related]  

  • 13. Comment on "Oral diabetes medications other than dipeptidyl peptidase-4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case-control study" and a case report of glucagon-like peptide-1 receptor agonist-induced bullous pemphigoid.
    Schwager Z; Mikailov A; Lipworth AD
    J Am Acad Dermatol; 2019 Jun; 80(6):e189-e190. PubMed ID: 30738123
    [No Abstract]   [Full Text] [Related]  

  • 14. Reply to: "Comment on 'Oral diabetes medications other than dipeptidyl peptidase-4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case control study'".
    Varpuluoma O; Huilaja L; Tasanen K
    J Am Acad Dermatol; 2018 Dec; 79(6):e113-e114. PubMed ID: 30420010
    [No Abstract]   [Full Text] [Related]  

  • 15. Comment on "Oral diabetes medications other than dipeptidyl peptidase-4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case control study".
    Kridin K
    J Am Acad Dermatol; 2018 Dec; 79(6):e111-e112. PubMed ID: 30420009
    [No Abstract]   [Full Text] [Related]  

  • 16. Oral diabetes medications other than dipeptidyl peptidase 4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case-control study.
    Varpuluoma O; Försti AK; Jokelainen J; Turpeinen M; Timonen M; Tasanen K; Huilaja L
    J Am Acad Dermatol; 2018 Dec; 79(6):1034-1038.e5. PubMed ID: 29803903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of diabetes mellitus in bullous pemphigoid patients in the absence of dipeptidyl peptidase-4 inhibitors: a systematic review and meta-analysis.
    Guo W; Rathi S; Marquez J; Smith H; Kuruvilla A; Tonnesen MG; Salvemini JN
    Arch Dermatol Res; 2023 Oct; 315(8):2207-2213. PubMed ID: 36867222
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.